keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma recent advances

keyword
https://www.readbyqxmd.com/read/29158695/pnpla3-expression-and-its-impact-on-the-liver-current-perspectives
#1
REVIEW
Francesca Virginia Bruschi, Matteo Tardelli, Thierry Claudel, Michael Trauner
A single-nucleotide polymorphism occurring in the sequence of the human patatin-like phospholipase domain-containing 3 gene (PNPLA3), known as I148M variant, is one of the best characterized and deeply investigated variants in several clinical scenarios, because of its tight correlation with increased risk for developing hepatic steatosis and more aggressive part of the disease spectrum, such as nonalcoholic steatohepatitis, advanced fibrosis and cirrhosis. Further, the I148M variant is positively associated with alcoholic liver diseases, chronic hepatitis C-related cirrhosis and hepatocellular carcinoma...
2017: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29152431/intensity-modulated-proton-therapy-with-advanced-planning-techniques-in-a-challenging-hepatocellular-carcinoma-patient
#2
Smith Apisarnthanarax, Jatinder Saini, Avril O'Ryan-Blair, Jackie Castro, Stephen R Bowen
The use of radiation therapy has been increasing over recent years for the treatment of hepatocellular carcinoma (HCC). Proton beam therapy (PBT) has emerged as a promising treatment option for HCC patients due to its dosimetric advantages of sparing more normal liver tissue from radiation at low to moderate doses compared to photon-based treatments while still delivering high doses of radiation to tumors. The PBT therapy may be particularly beneficial in high-risk HCC cirrhotic patients with large, bulky tumors and/or vascular invasion complicated by surrounding perfusion abnormalities...
September 10, 2017: Curēus
https://www.readbyqxmd.com/read/29152116/microrna-526b-servers-as-a-prognostic-factor-and-exhibits-tumor-suppressive-property-by-targeting-sirtuin-7-in-hepatocellular-carcinoma
#3
Xin Liu, Liu Yang, Jianfeng Tu, Wenwei Cai, Meiqi Zhang, Zhangxuan Shou, Yingmin Yao, Qiuran Xu
Recent studies have reported that microRNA-526b (miR-526b) is implicated in the growth and metastasis of cancer cells. However, the clinical significance of miR-526b and its role as well as underlying mechanisms are largely unknown in hepatocellular carcinoma (HCC). Here, we detected miR-526b expression difference between HCC and matched nontumor tissues with qRT-PCR. We found that miR-526b displayed lower expression in HCC patient tissues and cells. Clinical analysis revealed that low miR-526b expression correlated with large tumor size, venous infiltration, advanced tumor-node-metastasis (TNM) stage...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29150921/tgf-%C3%AE-and-hepatocellular-carcinoma-when-a-friend-becomes-an-enemy
#4
Marco Arrese, Daniel Cabrera, Alejandra Hernandez, Luis Astete, Lisbell Estrada, Claudio Cabello-Verrugio
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy...
November 16, 2017: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/29150490/gut-roundtable-meeting-paper-selected-recent-advances-in-hepatocellular-carcinoma
#5
REVIEW
Alexander Gerbes, Fabien Zoulim, Herbert Tilg, Jean-François Dufour, Jordi Bruix, Valérie Paradis, Riad Salem, Markus Peck-Radosavljevic, Peter R Galle, Tim F Greten, Jean-Charles Nault, Matias A Avila
Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy...
November 17, 2017: Gut
https://www.readbyqxmd.com/read/29113334/exosomal-mir-665-as-a-novel-minimally-invasive-biomarker-for-hepatocellular-carcinoma-diagnosis-and-prognosis
#6
Zhen Qu, Junhua Wu, Junyi Wu, Anlai Ji, Guanghui Qiang, Yong Jiang, Chunping Jiang, Yitao Ding
Recent studies have shown that circulating microRNAs are potential biomarkers for various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs (miRNAs) as novel serological biomarkers for hepatocellular carcinoma (HCC) diagnosis and prognosis. Exosomes are small membranous vesicles (30-100 nm). Exosomal miR-665 levels in HCC patients were significantly higher than those in healthy subjects (P < 0.05), and exosomal miR-665 levels were significantly upregulated in tumours larger in size (> 5 cm), in tumours with local invasion and in those at an advanced clinical stage (stage III/IV) of HCC (P = 0...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29113030/recent-advances-in-transarterial-embolotherapies-in-the-treatment-of-hepatocellular-carcinoma
#7
Edward Wolfgang Lee, Sarah Khan
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC...
November 8, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29108920/correlation-of-lysosome-associated-protein-transmembrane-4%C3%AE-gene-overexpression-with-the-malignant-phenotypes-of-hepatocellular-carcinoma
#8
Hongying Su, Tao Xu, Xiongfei Huang, Shengbing Zang, Bin Wang, Yang Huang, Jingfeng Liu, Aimin Huang
Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies, for which hepatitis B virus (HBV) chronic infection constitutes a major risk factor. The lysosome-associated protein transmembrane-4 β gene (LAPTM4B) is a recently identified gene that was found to be overexpressed in several types of cancer. However, the role of LAPTM4B in HCC tumorigenesis and progression has not been clearly determined. The present study demonstrated that the mRNA as well as the protein levels of LAPTM4B were significantly upregulated in HCC specimens...
October 7, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29105284/estimating-hcv-disease-burden-volume-4-editorial
#9
G J Dore, A Hatzakis, F Negro, I Waked
Hepatitis C virus (HCV) is a major global public health issue, with an estimated 71 million people living with HCV infection and a rising burden of cirrhosis, hepatocellular carcinoma (HCC) and liver-related mortality. The advent of interferon-free, direct acting antiviral-based (DAA) therapies, with short duration (8-12 weeks), high efficacy, excellent tolerability and ease of delivery (once daily oral dosing), is one of the major advances in clinical medicine in recent decades, and provides the opportunity to address this growing global HCV burden...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29096967/hepatocellular-carcinoma-present-and-future
#10
REVIEW
Carolina Armengol, Maria Rosa Sarrias, Margarita Sala
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related death, with a growing incidence in recent years. This tumor usually arises in patients with an underlying chronic liver disease. The management of this tumor has improved over the past 2 decades: patients at risk are included in a surveillance program, a prognostic staging system has been created and, finally, new treatments particularly aimed at patients with advanced HCC have been developed...
October 30, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29096734/endocrine-adiponectin-fgf15-19-axis-in-ethanol-induced-inflammation-and-alcoholic-liver-injury
#11
Min You, Zhou Zhou, Michael Daniels, Alvin Jogasuria
Alcoholic liver disease (ALD) is the most prevalent form of liver diseases, encompassing a spectrum of progressive pathological changes from steatosis to steatohepatitis to fibrosis/cirrhosis and hepatocellular carcinoma. Alcoholic steatosis/steatohepatitis is the initial stage of ALD and a major risk factor for advanced liver injuries. Adiponectin is a hormone secreted from adipocytes. Fibroblast growth factor (FGF) 15 (human homolog, FGF19) is an ileum-derived hormone. Adipocyte-derived adiponectin and gut-derived FGF15/19 regulate each other, share common signaling cascades and exert similar beneficial functions...
November 2, 2017: Gene Expression
https://www.readbyqxmd.com/read/29076939/transarterial-chemoembolization-for-hepatocellular-carcinoma-development-and-external-validation-of-the-munich-tace-score
#12
Mark Op den Winkel, Dorothea Nagel, Philip Op den Winkel, Jörg Trojan, Philipp M Paprottka, Christian J Steib, Laura Schmidt, Markus Göller, Petra Stieber, Peter Göhring, Andreas Herbst, Markus Rentsch, Enrico N De Toni, Burkhard Göke, Alexander L Gerbes, Frank T Kolligs
BACKGROUND: Allocation of patients with hepatocellular carcinoma (HCC) to the adequate therapy is determined by both tumor burden and liver function. The Barcelona Clinic Liver Cancer (BCLC) staging system and therapeutic algorithm recommends transarterial chemoembolization (TACE) based on the best evidence available to patients with intermediate-stage HCC (BCLC-B). However, many centers also treat subgroups of patients outside these recommendations and with more advanced disease by TACE...
October 25, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29072690/the-non-invasive-serum-biomarker-soluble-axl-accurately-detects-advanced-liver-fibrosis-and-cirrhosis
#13
Katharina Staufer, Mirko Dengler, Heidemarie Huber, Rodrig Marculescu, Rudolf Stauber, Carolin Lackner, Hans-Peter Dienes, Danijel Kivaranovic, Christian Schachner, Markus Zeitlinger, Beatrix Wulkersdorfer, Peter Rauch, Gerhard Prager, Michael Trauner, Wolfgang Mikulits
Soluble Axl (sAxl) was recently shown to be strongly released into the blood during liver fibrogenesis and hepatocellular carcinoma suggesting sAxl as a biomarker of liver diseases. In this study we are the first to evaluate sAxl in human serum in comparison to Enhanced Liver Fibrosis (ELF) test and transient elastography (TE; Fibroscan) for its value to detect significant (F≥2), advanced fibrosis (F≥3), and cirrhosis (F4) in different liver disease etiologies and healthy controls. To properly determine the diagnostic accuracy of sAxl, a test cohort as well as a validation cohort was employed using liver biopsy as a reference method...
October 26, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/29069821/combination-treatment-of-ergosterol-followed-by-amphotericin-b-induces-necrotic-cell-death-in-human-hepatocellular-carcinoma-cells
#14
Yu-Chun Lin, Bao-Hong Lee, Jassey Alagie, Ching-Hua Su
The incidence of liver cancer, the second leading cause of cancer-related deaths has increased over the past few decades. Although recent treatments such as sorafenib are promising in patients with advanced hepatocellular carcinoma (HCC), the response rates remain poor thereby warranting the identification of novel therapeutic agents against liver cancer. Herein, we investigated the anti-cancer effect of ergosterol (a secondary metabolite in medicinal fungus) pretreatment followed by amphotericin B (AmB) treatment on liver cancer cell lines...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29061150/dysregulated-long-noncoding-rnas-lncrnas-in-hepatocellular-carcinoma-implications-for-tumorigenesis-disease-progression-and-liver-cancer-stem-cells
#15
REVIEW
Xiaoqi Huo, Shuanglin Han, Guang Wu, Olivier Latchoumanin, Gang Zhou, Lionel Hebbard, Jacob George, Liang Qiao
Hepatocellular carcinoma (HCC) is one of the most common malignant tumours with a poor prognosis worldwide. While early stage tumours can be treated with curative approaches such as liver transplantation or surgical resection, these are only suitable for a minority of patients. Those with advanced stage disease are only suitable for supportive approaches and most are resistant to the conventional chemotherapy or radiotherapy. Liver cancer stem cells (LCSCs) are a small subset of cancer cells with unlimited differentiation ability and tumour forming potential...
October 23, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/29055114/sorafenib-response-in-hepatocellular-carcinoma-micrornas-as-tuning-forks-mirnas-as-regulators-of-sorafenib-response-in-hcc
#16
REVIEW
Shruthi Kanthaje, Ankita Makol, Anuradha Chakraborti
Hepatocellular carcinoma (HCC), the primary liver malignancy attributes towards the second foremost cause of cancer related mortality. The targeted chemotherapeutic agent, sorafenib is known to exhibit a statistically significant but limited overall survival advantage in advanced HCC. However, the individual patient response towards sorafenib varies drastically with most of them demonstrating stable disease (SD), few with partial response (PR) and very rare complete response (CR). Progressive disease (PD) despite the treatment has also been demonstrated in many patients indicating drug resistance...
October 20, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29054475/new-insights-into-sorafenib-resistance-in-hepatocellular-carcinoma-responsible-mechanisms-and-promising-strategies
#17
REVIEW
Leilei Niu, Liping Liu, Shengli Yang, Jianwei Ren, Paul B S Lai, George G Chen
It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a significant survival benefit from the sorafenib treatment, which is currently regarded as a first-line chemotherapeutic therapy in patients with advanced HCC. Most patients are highly refractory to this therapy. Therefore, it is necessary to identify resistant factors and explore potential protocols that can be used to overcome the resistance or substitute sorafenib once the resistance is formed. In fact, a growing body of studies has been focusing on the resistance mechanisms or the method to overcome it...
October 17, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29052780/immunotherapy-for-hepatocellular-carcinoma-patients-is-it-ready-for-prime-time
#18
REVIEW
Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, Timothy N Bullock, Craig L Slingluff, Osama E Rahma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it arises in an inflammatory milieu due to hepatitis B and C infections and cirrhosis. However, a major barrier to the development and success of immunotherapy in patients with HCC is the liver's inherent immunosuppressive function...
October 20, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29051790/current-immunotherapeutic-strategies-in-hepatocellular-carcinoma-recent-advances-and-future-directions
#19
REVIEW
Hwi Young Kim, Joong-Won Park
Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immune evasion by the disease, makes HCC a less promising target for conventional immunotherapy. However, recent advances in the immunotherapy have led to novel approaches to overcome these obstacles by manipulating and enhancing tumor-specific immune responses against HCC by using various modalities, such as cancer vaccines and immune checkpoint blockade...
October 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29040989/hepatocellular-carcinoma-after-achievement-of-sustained-viral-response-with-daclatasvir-and-asunaprevir-in-patients-with-chronic-hepatitis-c-virus-infection
#20
Hiroshi Ida, Satoru Hagiwara, Masashi Kono, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Masahiro Takita, Norihisa Yada, Yasunori Minami, Kazuomi Ueshima, Naoshi Nishida, Masatoshi Kudo
BACKGROUND: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection...
2017: Digestive Diseases
keyword
keyword
69280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"